Home >> Research Area >>Neuroscience>>5-HT Receptor>> Alosetron Hydrochloride

Alosetron Hydrochloride

5-HT3 receptor antagonist,potent and highly selective CAS# 122852-69-1

Alosetron Hydrochloride

Catalog No. BCC1344----Order now to get a substantial discount!

Product Name & Size Price Stock
Alosetron Hydrochloride: 5mg $35 In Stock
Alosetron Hydrochloride: 10mg Please Inquire In Stock
Alosetron Hydrochloride: 20mg Please Inquire Please Inquire
Alosetron Hydrochloride: 50mg Please Inquire Please Inquire
Alosetron Hydrochloride: 100mg Please Inquire Please Inquire
Alosetron Hydrochloride: 200mg Please Inquire Please Inquire
Alosetron Hydrochloride: 500mg Please Inquire Please Inquire
Alosetron Hydrochloride: 1000mg Please Inquire Please Inquire
Related Products

Quality Control of Alosetron Hydrochloride

Number of papers citing our products

Chemical structure

Alosetron Hydrochloride

3D structure

Chemical Properties of Alosetron Hydrochloride

Cas No. 122852-69-1 SDF Download SDF
PubChem ID 60758 Appearance Powder
Formula C17H19ClN4O M.Wt 330.81
Type of Compound N/A Storage Desiccate at -20°C
Synonyms 132414-02-9
Solubility H2O : 50 mg/mL (151.14 mM; Need ultrasonic)
Chemical Name 5-methyl-2-[(5-methyl-1H-imidazol-4-yl)methyl]-3,4-dihydropyrido[4,3-b]indol-1-one;hydrochloride
SMILES [H+].[Cl-].Cn1c2CCN(Cc3nc[nH]c3C)C(=O)c2c4ccccc14
Standard InChIKey FNYQZOVOVDSGJH-UHFFFAOYSA-N
Standard InChI InChI=1S/C17H18N4O.ClH/c1-11-13(19-10-18-11)9-21-8-7-15-16(17(21)22)12-5-3-4-6-14(12)20(15)2;/h3-6,10H,7-9H2,1-2H3,(H,18,19);1H
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.
We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months.
Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it.
About Packaging 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial.
2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial.
3. Try to avoid loss or contamination during the experiment.
Shipping Condition Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request.

Alosetron Hydrochloride Dilution Calculator

Concentration (start)
x
Volume (start)
=
Concentration (final)
x
Volume (final)
 
 
 
C1
V1
C2
V2

calculate

Alosetron Hydrochloride Molarity Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
g/mol

calculate

Preparing Stock Solutions of Alosetron Hydrochloride

1 mg 5 mg 10 mg 20 mg 25 mg
1 mM 3.0229 mL 15.1144 mL 30.2288 mL 60.4577 mL 75.5721 mL
5 mM 0.6046 mL 3.0229 mL 6.0458 mL 12.0915 mL 15.1144 mL
10 mM 0.3023 mL 1.5114 mL 3.0229 mL 6.0458 mL 7.5572 mL
50 mM 0.0605 mL 0.3023 mL 0.6046 mL 1.2092 mL 1.5114 mL
100 mM 0.0302 mL 0.1511 mL 0.3023 mL 0.6046 mL 0.7557 mL
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations.

Organizitions Citing Our Products recently

 
 
 

Calcutta University

University of Minnesota

University of Maryland School of Medicine

University of Illinois at Chicago

The Ohio State University

University of Zurich

Harvard University

Colorado State University

Auburn University

Yale University

Worcester Polytechnic Institute

Washington State University

Stanford University

University of Leipzig

Universidade da Beira Interior

The Institute of Cancer Research

Heidelberg University

University of Amsterdam

University of Auckland
TsingHua University
TsingHua University
The University of Michigan
The University of Michigan
Miami University
Miami University
DRURY University
DRURY University
Jilin University
Jilin University
Fudan University
Fudan University
Wuhan University
Wuhan University
Sun Yat-sen University
Sun Yat-sen University
Universite de Paris
Universite de Paris
Deemed University
Deemed University
Auckland University
Auckland University
The University of Tokyo
The University of Tokyo
Korea University
Korea University

Background on Alosetron Hydrochloride

Alosetron is s Serotonin 5HT3-receptor antagonist that is used in treatment of irritable bowel syndrome.

Featured Products
New Products
 

References on Alosetron Hydrochloride

Optimizing outcomes with alosetron hydrochloride in severe diarrhea-predominant irritable bowel syndrome.[Pubmed:21180598]

Therap Adv Gastroenterol. 2010 May;3(3):165-72.

Irritable bowel syndrome (IBS) is a highly prevalent functional gastrointestinal disorder that causes a range of symptoms. Currently, Alosetron Hydrochloride (Lotronex(R)), a selective serotonin type 3 receptor antagonist, is the only medication approved for the treatment of severe diarrhea-predominant irritable bowel syndrome (IBS-D) in women who have inadequately responded to conventional therapy. Alosetron has demonstrated efficacy compared with placebo in clinical trials and has been shown to improve overall health-related quality of life (HRQoL). However, rare instances of ischemic colitis and severe complications of constipation have been reported. As a result, in 2000 alosetron was voluntarily withdrawn from the market but was reintroduced in 2002 with a more restricted indication and a requirement that clinicians and patients follow a prescribing program. Although the efficacy and benefit of alosetron has been clearly demonstrated, it has been used sparingly since its reintroduction. This brief review describes the history of alosetron, efficacy of alosetron in the treatment of IBS, the impact of severe IBS on HRQoL, safety considerations, the risk evaluation and mitigation strategy program under which alosetron is now prescribed, and an update on postmarketing surveillance data.

Incidence of colonic ischemia, hospitalized complications of constipation, and bowel surgery in relation to use of alosetron hydrochloride.[Pubmed:12809837]

Am J Gastroenterol. 2003 May;98(5):1117-22.

OBJECTIVE: Alosetron Hydrochloride (Lotronex), a potent selective 5-hydroxytryptamine(3) receptor antagonist, was approved in February, 2000 in the United States for the treatment of diarrhea-predominant irritable bowel syndrome (IBS) in women. Marketing was suspended in November, 2000, after reports of colonic ischemia and serious complications of constipation. We sought to compare the incidence of colonic ischemia, hospitalized complications of constipation, and bowel surgery among alosetron users and a cohort of patients with IBS who did not use alosetron. METHODS: We sought outcomes of colonic ischemia, hospitalized complications of constipation, and bowel surgery in 3,631 Lotronex users and 2,480 comparison IBS subjects using diagnoses, procedures, and drugs recorded in the UnitedHealthcare insurance claims database, and validated these by chart review. The initial assessment was to last for 3 yr beginning with the start of alosetron treatment and was to include 10,000 Lotronex users; however, the observation period ended by December 31, 2000, after suspension of marketing. RESULTS: There were 3631 alosetron users among members of UnitedHealthcare from March through December, 2000, and we identified 2480 comparison IBS-only patients; follow-up time averaged about 5 months in both groups. There were no instances of colonic ischemia in either cohort. Thirty instances of bowel surgery occurred, giving rates of 10.2/1000 person-yr in the alosetron cohort and 11.8/1000 person-yr in the IBS/no alosetron cohort. There were three cases of hospitalized complications of constipation. The incidence rates were essentially the same in alosetron users (1.24/1000 person-yr) and in IBS patients with no alosetron use (0.92/1000 person-yr). CONCLUSIONS: Alosetron users did not differ from IBS patients not using alosetron in the incidence of bowel surgery or hospitalized complications of constipation; there were no cases of colonic ischemia. The statistical upper limit of colonic ischemia rates in alosetron users was 2.28/1000 person-yr. Because of the market withdrawal, the size of the cohort and the duration of follow-up were smaller than originally planned; consequently, the statements about the safety of alosetron were necessarily limited. On June 7, 2002, the Food and Drug Administration approved alosetron for reintroduction in the U.S. market for women with severe diarrhea-related IBS.

Description

Alosetron Hydrochloride (GR 68755 Hydrochloride) is a Serotonin 5HT3-receptor antagonist that is used in treatment of irritable bowel syndrome.

Keywords:

Alosetron Hydrochloride,122852-69-1,132414-02-9,Natural Products,5-HT Receptor, buy Alosetron Hydrochloride , Alosetron Hydrochloride supplier , purchase Alosetron Hydrochloride , Alosetron Hydrochloride cost , Alosetron Hydrochloride manufacturer , order Alosetron Hydrochloride , high purity Alosetron Hydrochloride

Online Inquiry for:

      Fill out the information below

      • Size:Qty: - +

      * Required Fields

                                      Result: